Morningstar Acciones

无锡药明生物技术有限公司 02269 StarRatingValueLabel_5Mr. Lee Davidson, Head of Quantitative Research

Último Precio
13,48
Cambio del día
0,74|5,81%

a 26/04/2024
16:08:19 HKT | HKD  Minimum 15 Minutes Delay.

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
13,46 - 13,4812,62 - 13,6255.504.71568.526.78056,11Bil
Último Cierre52 Week RangeP/BeneficioDividendo %ISIN
12,7412,42 - 52,4516,20-KYG970081173

Cotización WuXi Biologics (Cayman) Inc

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202020212022
More...
Cuenta de Resultados
Ingresos5.612,3810.290,0515.268,66
Operating Income1.761,543.464,674.798,36
Resultado Neto1.688,893.388,484.420,29
Beneficio Básico por Acción0,430,811,06
Num Medio Acciones diluidas en circulación4.2094.4224.376
Balance
Activo Corriente14.204,3719.529,7418.469,87
Activos no corrientes14.759,2524.502,8831.094,52
Total Activo 28.963,6144.032,6249.564,39
Pasivo corriente4.498,258.255,699.318,60
Total Pasivo---
Total Equity20.564,4532.278,5935.047,41
Flujo de Caja
Flujo de caja operativo1.881,283.431,265.541,67
Inversiones de Capital-6.024,78-6.523,11-5.868,39
Flujo de Caja Libre-4.143,50-3.091,86-326,72

En millones, excepto "EPS básico". Currency is CNY.

Perfil de la compañía

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 17 billion. North America represented 47.4% of total revenue in 2023. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

Sector

Atención sanitaria

Industria

Biotecnología

Estilo de acciones

Grande-Crecim

Fin Ejercicio Fiscal

diciembre

Empleados

12.740
Datos destacados
More...
Precio/Beneficio 12 m-
Precio/Valor contable1,22
Price/Sales TTM-
Crec Ingresos (media 3 a)56,50
Crec BPA (media 3 a)-
Margen operativo31,43
Margen neto28,95
ROE 12 m13,13
Deuda/Fondos propios0,08
Dividendos
AntLatest
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0,000,00
Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
© Copyright 2024 Morningstar, Inc. Reservados todos los derechos.

Términos de uso        Política Privacidad        Cookie Settings        Aviso Legal